This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 31.19% and 8.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Abbott Laboratories (ABT) in Q2 Earnings?
by Zacks Equity Research
Excluding COVID testing sales, Abbott's (ABT) worldwide Diagnostic sales are expected to have demonstrated strong growth in Q2 on the continuous rollout of Alinity.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $106.21, marking a -1.93% move from the previous day.
Earnings Preview: Abbott (ABT) Q2 Earnings Expected to Decline
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $109.49 in the latest trading session, marking a +0.74% move from the prior day.
The Zacks Analyst Blog Highlights Abbott, T-Mobile US, Intuit, Analog Devices and The Progressive
by Zacks Equity Research
Abbott, T-Mobile US, Intuit, Analog Devices and The Progressive are part of Zacks top Analyst Blog.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $110.22 in the latest trading session, marking a +1.45% move from the prior day.
Top Stock Reports for Abbott Laboratories, T-Mobile & Intuit
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), T-Mobile US, Inc. (TMUS) and Intuit Inc. (INTU).
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $109.10, moving +1.99% from the previous trading session.
ESLOY or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ESLOY vs. ABT: Which Stock Is the Better Value Option?
Strength Seen in Abbott (ABT): Can Its 3.1% Jump Turn into More Strength?
by Zacks Equity Research
Abbott (ABT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $106.21, marking a +0.73% move from the previous day.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $104.41, marking a +1.83% move from the previous day.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $104.80, marking a +1.81% move from the previous day.
ESLOY vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ESLOY vs. ABT: Which Stock Is the Better Value Option?
Abbott (ABT) Medical Devices Arm Gains Traction, FX Woe Stays
by Zacks Equity Research
Within Abbott's (ABT) Nutrition arm, while the pediatric nutrition business witnesses a drag, the adult nutrition business continues to perform well.
The Zacks Analyst Blog Highlights Novo Nordisk, Toyota Motor, Salesforce, Abbott Laboratories, Raytheon Technologies, and Equinor
by Zacks Equity Research
Novo Nordisk, Toyota Motor, Salesforce, Abbott Laboratories, Raytheon Technologies, and Equinor are part of Zacks top Analyst Blog.
Abbott (ABT) Stock Moves -1.73%: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $112.71, marking a -1.73% move from the previous day.
Top Research Reports for Novo Nordisk, Toyota & Salesforce
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Toyota Motor Corporation (TM), and Salesforce, Inc. (CRM).
Abbott (ABT) FreeStyle Libre 3 System's Study Outcome Favorable
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre 3 system is the first and only 14-day CGM system with an overall MARD of 7.9%.
Abbott (ABT) Stock Moves -0.8%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $116.57, moving -0.8% from the previous trading session.
Cardiovascular Systems (CSII) Up 0.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott (ABT) Receives FDA Nod for FreeStyle Libre 3 System
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre 3 system offers greater accuracy and easier application compared with other CGMs.
ESLOY vs. ABT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ESLOY vs. ABT: Which Stock Is the Better Value Option?